FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966331477> ?p ?o ?g. }

• W1966331477 endingPage "351" @default.
• W1966331477 startingPage "343" @default.
• W1966331477 abstract "The IFN-gamma-inducible and CXCR3-targeting human CXC chemokines CXCL9 (Mig) and CXCL10 (IP10) have potent antitumor activity through attraction of cytotoxic T lymphocytes and inhibition of angiogenesis. The more recently identified CXCR3-targeting chemokine CXCL11 (I-TAC/IP9) proved to be a more potent chemokine than CXCL9 and CXCL10 in vitro, both in chemotaxis assays with CXCR3+ T lymphocytes and in calcium mobilization experiments. However, its antitumor activity in vivo has not been shown so far. To investigate this, mice were challenged with EL4 T-cell lymphoma cells, genetically modified to produce murine CXCL11. Tumor growth curves showed complete rejection of CXCL11-producing tumors but not of control tumors. Tumor infiltrate analysis by flow cytometry showed a clear correlation between rejection of CXCL11-producing tumors and an increase of tumor-infiltrating CD8+CXCR3+ as well as CD8+CXCR3- T lymphocytes. In vivo CD8 T-cell depletion completely abrogated the antitumor effect. No difference in angiogenesis between control and CXCL11-producing tumors was observed. In survivors, rechallenge experiments with wild-type tumor cells suggested development of protective antitumor immunity involving tumor-specific IFN-gamma production by CD8+ T lymphocytes. These experiments show, for the first time, antitumor activity of CXCL11 in vivo, which warrants exploration for its potential role in anticancer immunotherapy." @default.
• W1966331477 created "2016-06-24" @default.
• W1966331477 creator A5005955733 @default.
• W1966331477 creator A5008094633 @default.
• W1966331477 creator A5011693763 @default.
• W1966331477 creator A5061757320 @default.
• W1966331477 creator A5069079748 @default.
• W1966331477 creator A5085426388 @default.
• W1966331477 date "2005-07-01" @default.
• W1966331477 modified "2023-09-27" @default.
• W1966331477 title "The CXCR3 Targeting Chemokine CXCL11 Has Potent Antitumor Activity In Vivo Involving Attraction of CD8+ T Lymphocytes But Not Inhibition of Angiogenesis" @default.
• W1966331477 cites W1491294598 @default.
• W1966331477 cites W1506086660 @default.
• W1966331477 cites W1525077036 @default.
• W1966331477 cites W1534766853 @default.
• W1966331477 cites W1563246330 @default.
• W1966331477 cites W1751960924 @default.
• W1966331477 cites W1779967726 @default.
• W1966331477 cites W1789525127 @default.
• W1966331477 cites W1964910994 @default.
• W1966331477 cites W1975684997 @default.
• W1966331477 cites W1981951675 @default.
• W1966331477 cites W1995827621 @default.
• W1966331477 cites W2010003229 @default.
• W1966331477 cites W2012208053 @default.
• W1966331477 cites W2017959839 @default.
• W1966331477 cites W2042383304 @default.
• W1966331477 cites W2075853586 @default.
• W1966331477 cites W2095354110 @default.
• W1966331477 cites W2104596858 @default.
• W1966331477 cites W2109314033 @default.
• W1966331477 cites W2118526748 @default.
• W1966331477 cites W2128417084 @default.
• W1966331477 cites W2134768631 @default.
• W1966331477 cites W2136451405 @default.
• W1966331477 cites W2141910551 @default.
• W1966331477 cites W2143920564 @default.
• W1966331477 cites W2150782063 @default.
• W1966331477 cites W2156323704 @default.
• W1966331477 cites W2159520551 @default.
• W1966331477 cites W2167711236 @default.
• W1966331477 cites W2170547143 @default.
• W1966331477 cites W2316311853 @default.
• W1966331477 cites W2402533012 @default.
• W1966331477 cites W4313343514 @default.
• W1966331477 doi "https://doi.org/10.1097/01.cji.0000165355.26795.27" @default.
• W1966331477 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16000952" @default.
• W1966331477 hasPublicationYear "2005" @default.
• W1966331477 type Work @default.
• W1966331477 sameAs 1966331477 @default.
• W1966331477 citedByCount "115" @default.
• W1966331477 countsByYear W19663314772012 @default.
• W1966331477 countsByYear W19663314772013 @default.
• W1966331477 countsByYear W19663314772014 @default.
• W1966331477 countsByYear W19663314772015 @default.
• W1966331477 countsByYear W19663314772016 @default.
• W1966331477 countsByYear W19663314772017 @default.
• W1966331477 countsByYear W19663314772018 @default.
• W1966331477 countsByYear W19663314772019 @default.
• W1966331477 countsByYear W19663314772020 @default.
• W1966331477 countsByYear W19663314772021 @default.
• W1966331477 countsByYear W19663314772022 @default.
• W1966331477 countsByYear W19663314772023 @default.
• W1966331477 crossrefType "journal-article" @default.
• W1966331477 hasAuthorship W1966331477A5005955733 @default.
• W1966331477 hasAuthorship W1966331477A5008094633 @default.
• W1966331477 hasAuthorship W1966331477A5011693763 @default.
• W1966331477 hasAuthorship W1966331477A5061757320 @default.
• W1966331477 hasAuthorship W1966331477A5069079748 @default.
• W1966331477 hasAuthorship W1966331477A5085426388 @default.
• W1966331477 hasConcept C116484652 @default.
• W1966331477 hasConcept C12823836 @default.
• W1966331477 hasConcept C13373296 @default.
• W1966331477 hasConcept C13425408 @default.
• W1966331477 hasConcept C143172330 @default.
• W1966331477 hasConcept C147483822 @default.
• W1966331477 hasConcept C150903083 @default.
• W1966331477 hasConcept C154317977 @default.
• W1966331477 hasConcept C167672396 @default.
• W1966331477 hasConcept C17502307 @default.
• W1966331477 hasConcept C185592680 @default.
• W1966331477 hasConcept C202751555 @default.
• W1966331477 hasConcept C203014093 @default.
• W1966331477 hasConcept C207001950 @default.
• W1966331477 hasConcept C25532541 @default.
• W1966331477 hasConcept C2780394083 @default.
• W1966331477 hasConcept C45240729 @default.
• W1966331477 hasConcept C502942594 @default.
• W1966331477 hasConcept C55493867 @default.
• W1966331477 hasConcept C5858377 @default.
• W1966331477 hasConcept C79484868 @default.
• W1966331477 hasConcept C86803240 @default.
• W1966331477 hasConcept C8891405 @default.
• W1966331477 hasConceptScore W1966331477C116484652 @default.
• W1966331477 hasConceptScore W1966331477C12823836 @default.
• W1966331477 hasConceptScore W1966331477C13373296 @default.
• W1966331477 hasConceptScore W1966331477C13425408 @default.
• W1966331477 hasConceptScore W1966331477C143172330 @default.

• next